BOXR: A Platform for Improving T-Cell Performance in the Solid Tumour Microenvironment

Time: 1:45 pm
day: Day 2 - Track A - Afternoon


  • BOXR Bolt-On CHImeric Receptor is a platform to identify novel transgenes that can enhance CAR-T performance in the solid tumour microenvironment
  • BOXR1030 is SOTIO’s first clinical candidate. It is a GPC3-targeted CAR-T enhanced with the mitochondrial enzyme GOT2 which enhances T-cell performance in low glucose and low oxygen in vitro models and stringent xenograft models